Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma
Open Access
- 8 September 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 32682
Abstract
In neuroblastoma (NB), one of the most common paediatric solid tumours, activation of anaplastic lymphoma kinase (ALK) is often associated with poor outcomes. Although genetic studies have identified copy number alteration and nonsynonymous mutations of ALK, the regulatory mechanism of ALK signalling at protein levels is largely elusive. Neuronal leucine-rich repeat 1 (NLRR1) is a type 1 transmembrane protein that is highly expressed in unfavourable NB and potentially influences receptor tyrosine kinase signalling. Here, we showed that NLRR1 and ALK exhibited a mutually exclusive expression pattern in primary NB tissues by immunohistochemistry. Moreover, dorsal root ganglia of Nlrr1+/+ and Nlrr1−/− mice displayed the opposite expression patterns of Nlrr1 and Alk. Of interest, NLRR1 physically interacted with ALK in vitro through its extracellular region. Notably, the NLRR1 ectodomain impaired ALK phosphorylation and proliferation of ALK-mutated NB cells. A newly identified cleavage of the NLRR1 ectodomain also supported NLRR1-mediated ALK signal regulation in trans. Thus, we conclude that NLRR1 appears to be an extracellular negative regulator of ALK signalling in NB and neuronal development. Our findings may be beneficial to comprehend NB heterogeneity and to develop a novel therapy against unfavourable NB.Keywords
This publication has 44 references indexed in Scilit:
- Secreted and O-GlcNAcylated MIF binds to the human EGF receptor and inhibits its activationNature Cell Biology, 2015
- Heparin is an activating ligand of the orphan receptor tyrosine kinase ALKScience Signaling, 2015
- Anaplastic Lymphoma Kinase Is Required for Neurogenesis in the Developing Central Nervous System of ZebrafishPLOS ONE, 2013
- Activated ALK Collaborates with MYCN in Neuroblastoma PathogenesisCancer Cell, 2012
- Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in NeuroblastomaScience Translational Medicine, 2011
- High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary NeuroblastomaClinical Cancer Research, 2011
- Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN AmplificationClinical Cancer Research, 2010
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLCNature Reviews Clinical Oncology, 2009
- The leucine-rich repeat structureCellular and Molecular Life Sciences, 2008